FIG 1.

Kaplan-Meier estimates of PFS. The duration of PFS by investigator assessment is estimated via Kaplan-Meier methods. In tandem, hazard in the aumolertinib arm divided by the hazard in the gefitinib arm provided the hazard ratio. For the patients who discontinued study treatment or received new antitumor therapy treatment before progression or death, the patient was censored at the latest evaluable examination date of imaging before the discontinuation date or the date of starting new antitumor therapies. HR, hazard ratio; mPFS, median PFS; PFS, progression-free survival.